Observational Study of Sex Differences in Symptoms During Immune Checkpoint Inhibitor Treatment for People With Cancer
NCT06562777 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 100
Last updated 2025-10-31
Summary
This study aims to learn more about symptoms that patients experience while receiving immunotherapy for cancer.
Conditions
- Hematopoietic and Lymphatic System Neoplasm
- Malignant Solid Neoplasm
Interventions
- OTHER
-
Non-Interventional Study
Non-Interventional Study
Sponsors & Collaborators
-
Oregon Health and Science University
collaborator OTHER -
OHSU Knight Cancer Institute
lead OTHER
Principal Investigators
-
Deanne Tibbitts · OHSU Knight Cancer Institute
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-09-15
- Primary Completion
- 2026-03-01
- Completion
- 2026-03-01
Countries
- United States
Study Locations
More Related Trials
-
Evaluate the Efficacy and Safety of Activated T-lymphocyte Cell Therapy in Advanced Pancreatic Cancer
NCT00965718 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Blood Immune Cells in Cancer Patients Compared to Controls
NCT01312701 ·Status: UNKNOWN
-
Exploring Relevant Immune-based Biomarkers and Circulating Tumor Cells During Treatment With Immunotherapy in Genitourinary Malignancies (CTC Immune Based Biomarkers)
NCT02978118 ·Status: ACTIVE_NOT_RECRUITING
-
The Effect of Education and Telephone Follow-up Given to Cancer Patients Receiving Immunotherapy on Symptom Management and Self-care Power
NCT05683652 ·Status: UNKNOWN ·Phase: NA
-
Characterisation of TLR4+ Blood Cells in Patients With Solid Cancer
NCT06131775 ·Status: RECRUITING ·Phase: NA
-
GI Complications in Cancer Immunotherapy Patients
NCT02784366 ·Status: UNKNOWN
-
Lymphocytes Subpopulation in Cancer Patients
NCT02516371 ·Status: UNKNOWN ·Phase: NA
-
Study of DC-CIK Combined With Chemotherapy for Advanced Solid Tumor
NCT04214717 ·Status: UNKNOWN ·Phase: NA
-
Identification of Innovative Biomarkers Related to the Immune System or Tumor Microenvironment to Promote the Efficacy of Immunotherapies
NCT06626269 ·Status: RECRUITING ·Phase: NA
-
Evaluating Immune Response to COVID-19 Vaccines in Patients With Cancer, Transplant or Cellular Therapy Recipients
NCT05164016 ·Status: COMPLETED
-
A Phase 1 Study of MEDI0562 in Adult Subjects With Selected Advanced Solid Tumors
NCT02318394 ·Status: COMPLETED ·Phase: PHASE1
-
Biological Therapy in Treating Patients With Advanced Cancer
NCT00005956 ·Status: COMPLETED ·Phase: NA
-
Immunogenicity and Safety of COVID-19 Vaccine in Cancer Patients
NCT04910295 ·Status: COMPLETED
-
Immunogenicity and Safety of Pneumococcal Vaccination in Patients Treated With Immune Checkpoint Inhibitors
NCT03989050 ·Status: WITHDRAWN
-
ImmuNe ParameTERs to Predict Immunotherapy REsponse and Toxicity (INTERPRET)
NCT06900296 ·Status: NOT_YET_RECRUITING
-
Clinical Efficacy and Safety of Dendritic Cytotoxic Lymphocyte(DC-CTL) Cell Infusion in NSCLC Patients
NCT02766348 ·Status: UNKNOWN ·Phase: PHASE2
-
Phase I Study of OriC902 in Treatment of Advanced HCC
NCT06891742 ·Status: RECRUITING ·Phase: PHASE1
-
Immuno-Oncology Database and Bioregistry
NCT04656873 ·Status: ACTIVE_NOT_RECRUITING
-
Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma
NCT01875653 ·Status: TERMINATED ·Phase: PHASE3
-
Safety and Effectiveness Study of Autologous Natural Killer and Natural Killer T Cells on Cancer
NCT00909558 ·Status: SUSPENDED ·Phase: PHASE1
-
Immunotherapy & Me
NCT03347058 ·Status: COMPLETED ·Phase: NA
-
SYSTEMATIC SYMPTOM ASSESSMENT IN CANCER PATIENTS TREATED WITH IMMUNE CHECKPOINT INHIBITORS
NCT04929353 ·Status: UNKNOWN ·Phase: NA
-
Modulation of Immune Response by Oral Zinc Supplementation in Chemotherapy for Colon Cancer
NCT01261962 ·Status: UNKNOWN ·Phase: NA
-
Clinical Efficacy and Safety of NKT Cell Infusion in Patients With Advanced Solid Tumor
NCT02562963 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Immunity to Infection in Healthy Participants and Participants With Cancer
NCT05787964 ·Status: ACTIVE_NOT_RECRUITING